oru.sePublikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study
Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium; Department of Chronic Diseases, Metabolism and Ageing, Ku Leuven, Leuven, Belgium.
Erasmus MC, Rotterdam, Netherlands.
Aarhus University Hospital, Aarhus, Denmark.ORCID-id: 0000-0003-3070-8950
Ziekenhuis Oost‐Limburg ‐ Campus Sint‐Jan, Genk, Belgium.
Vise andre og tillknytning
2020 (engelsk)Inngår i: Alimentary Pharmacology and Therapeutics, ISSN 0269-2813, E-ISSN 1365-2036, Vol. 51, nr 1, s. 129-138Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Background: Women with inflammatory bowel diseases (IBD) often receive biologicals during pregnancy to maintain disease remission. Data on outcome of vedolizumab-exposed pregnancies (VDZE) are sparse.

Aims: The aim was to assess pregnancy and child outcomes of VDZE pregnancies and to compare these results to anti-TNF exposed (TNFE) or both immunomodulatory and biologic unexposed (CON IBD) pregnancies.

Methods: A retrospective multicentre case-control observational study was performed.

Results: VDZE group included 79 pregnancies in 73 IBD women. The TNFE and CON IBD group included 186 pregnancies (162 live births) in 164 IBD women and 184 pregnancies (163 live births) in 155 IBD women, respectively. At conception, cases more often had active disease ([VDZE: 36% vs TNFE: 17%, P = .002] and [VDZE: 36% vs CON IBD: 24%, P = .063]). No significant difference in miscarriage rates were found between groups (VDZE and TNFE: 16% vs 13%, P = .567; VDZE and CON IBD: 16% vs 10%, P = .216). In live-born infants, median gestational age and birthweight were similar between groups. Median Apgar score at birth was numerically equal. Prematurity was similar in the VDZE group compared to the control groups, even when correcting for disease activity during pregnancy. The frequency of congenital anomalies was comparable between groups as were the percentages of breastfed babies. During the first year of life, no malignancies were reported and infants' infection risk did not significantly differ between groups.

Conclusion: No new safety signal was detected in VDZE pregnancies although larger, prospective studies are required for confirmation.

sted, utgiver, år, opplag, sider
Blackwell Publishing, 2020. Vol. 51, nr 1, s. 129-138
HSV kategori
Identifikatorer
URN: urn:nbn:se:oru:diva-77989DOI: 10.1111/apt.15539ISI: 000494518700001PubMedID: 31692017Scopus ID: 2-s2.0-85074778397OAI: oai:DiVA.org:oru-77989DiVA, id: diva2:1372311
Merknad

Funding Agencies:

Takeda Pharmaceutical Company Ltd

Johnson & Johnson USA

Janssen Biotech Inc

Tilgjengelig fra: 2019-11-22 Laget: 2019-11-22 Sist oppdatert: 2020-01-13bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMedScopus

Personposter BETA

Eriksson, Carl

Søk i DiVA

Av forfatter/redaktør
Julsgaard, MetteEriksson, Carl
Av organisasjonen
I samme tidsskrift
Alimentary Pharmacology and Therapeutics

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 41 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf